All Posts Tagged With: "LIFE"
(QGEN) Qiagen Beats Earnings Forecasts – Reiterates Outllook
Qiagen’s (QGEN) first quarter 2012 earnings of 12 cents per share remained flat on a year-over-year basis. However, adjusting for certain one-time items, EPS came in at 23 cents in the first quarter, beating...
(ILMN) Two Major Biotech Trends In 2012
by Marc Lichtenfeld, Investment U Senior...
(TMO) Thermo Fisher Scientific Shares Maintained at Neutral
Recently, we reiterated our Neutral recommendation on Thermo Fisher Scientific (TMO) with a target price of $47.00.
Thermo Fisher continues to be focused on effectively deploying its cash balance to...
(QGEN) Qiagen Added in Russell 1000 and 3000
Recently, Qiagen (QGEN) announced that it has been included in the Russell 1000 and the Russell 3000 Indices. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe...
(LIFE) Life Technologies Ties Up with Pharma Majors
Life Technologies Corporation (LIFE) recently strengthened its newly created Technology Strategy Board grant consortium with the inclusion of the R&D divisions of AstraZeneca...
(LMNX) Luminex MAGPIX Earns Stevie Award for Business
Luminex Corporation (LMNX), a developer of biological testing technologies, has clinched two American Business Awards (“Stevie Awards”) for its flagship MAGPIX analytical instrument. The Stevie Awards...
(QGEN) Qiagen Hopeful of Ipsogen Takeover
Recently, Qiagen (QGEN) entered into an agreement to acquire 47% stake in France based Ipsogen at €12.90 per share. Thereafter, Qiagen wishes to make a public offer to fully acquire the company. With Ipsogen,...
(LIFE) Life Technologies Deals with Luminex
Life Technologies Corporation (LIFE) recently entered into a global sales and distribution agreement with Luminex Corporation (LMNX) to...
(LMNX) Luminex Tops Earnings Estimates
Luminex Corporation (LMNX), a developer of biological testing technologies, posted first-quarter fiscal 2011 earnings per share of 11 cents, comfortably beating the Zacks Consensus Estimate of 6 cents and...
(AFFX) Affymetrix Analyst Initiates Shares at Neutral
We initiate our coverage on genetic products maker Affymetrix (AFFX) with a Neutral recommendation. The company posted respectable results in fourth-quarter fiscal 2010 with earnings beating the Zacks Consensus...
(LMNX) Luminex MAGPIX Wins MDEA
Luminex Corporation (LMNX), a developer of biological testing technologies, recently received the prestigious Medical Design Excellence Award (“MDEA”) for its MAGPIX analytical instrument. MDEA, organized...
(AEO) Company News for February 04, 2011 – Corporate Summary
• MasterCard (NYSE:MA) reported Q4 EPS of $3.16, lower than the Zacks Consensus Estimate of $3.98 per share. Revenues for the quarter rose 10.7% year-over-year to $1.44 billion, beating the Zacks Consensus Estimate of $1.436...
(LMNX) Luminex Earns FDA Approval for New Diagnostic Test
Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration...
(LMNX) Luminex Analyst Downgrades Shares to Underperform
We downgrade our recommendation on Luminex Corporation (LMNX) to Underperform following the company’s lower-than-expected third quarter results and a less favorable outlook. Third-quarter fiscal 2010 adjusted...
(WAT) Waters Corporation Earnings Slightly Below The Street
Waters Corp. (WAT) released its third quarter earnings before the market opened today, reporting earnings from continuing operation of 96 cents, slightly below the Zacks Consensus Estimate of 97 cents. Earnings...
(WAT) Waters Corporation Third Quarter 2010 Earnings Preview
Waters Corp. (WAT) is slated to report its third quarter 2010 earnings on October 26, 2010 before the opening bell. The current Zacks Consensus Estimate for the third quarter is 97 cents per share, representing...
(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit
I expect the 2010s to be the “Decade of Biotech.”
In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when...
(LIFE) Life Technologies Corporation Sells Mass Spectrometry Business
Life Technologies Corporation (LIFE) recently completed the sale of its mass spectrometry business to Danaher Corporation (DHR) for $450...
(DHR) Danaher Corporation Exceeds Expectations
Danaher Corp. (DHR) reported fourth-quarter earnings from continuing operations of $1.08 per share, which excludes additional restructuring charges, beating the Zacks Consensus Estimate of $1.
Quarterly...
(LIFE) Life Technologies Corporation Beats Expectations – Outlook Positive
Life Technologies Corporation (LIFE) reported fourth quarter earnings of 80 cents per share, well above the Zacks Consensus Estimate of 72 cents. The company reported earnings of 82 cents in the year-ago...
(WAT) Waters Corporation Matches Earnings Estimates
Waters Corporation (WAT) reported earnings per share of $1.10, excluding restructuring charges, for the fourth quarter of 2009, which matched the Zacks Consensus Estimate.
The company reported fourth...
(LMNX) Luminex Corporation Upgraded to Neutral
Recently, we upgraded Luminex Corp. (LMNX) to Neutral from Underperform. Our decision to upgrade the stock was based on the company’s wide range of products and its significant international presence. These...
(LMNX) Luminex Corporation Posts Loss
Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or 1 cent per share as opposed to a net income of $3.2 million or 8 cents in the comparable period of 2008. The Zacks Consensus Estimate...
(WAT) Waters Corporation Modestly Outperforms
Waters Corporation (WAT) reported third quarter 2009 revenues of $374 million, a decrease of 3% over that of $386 million in the third quarter of 2008. On a GAAP basis, earnings...
(LIFE) Life Technologies Corporation Beats
Life Technologies Corporation (LIFE) reported third quarter earnings of 73 cents per share, well above the Zacks Consensus Estimate of 61 cents. The company reported earnings of 63 cents in the year-ago period.
Strong...
(GHDX) Genomic Health’s Results Reveal Oncotype DX Utility
Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage...
(GHDX) Good News for Genomic Health
Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health’s Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about...
(DHR) Danaher Expands in Life Sciences
Earlier today, Danaher Corp. (DHR) announced its decision to acquire the Analytical Technologies division of MDS Inc. (MDZ). This includes a 50% stake in Applied Biosystems/MDS Sciex joint venture (AB SCIEX), and a 100% ownership in the former...